Mr. Thomas Smeenk reports

HEMOSTEMIX'S SOCIAL MEDIA FOR INVESTORS AND FLORIDA'S NO-OPTION PATIENTS

Hemostemix Inc. has made additions to its investor awareness and social media strategies and programs.

The investor outreach campaign includes:

• Opt-in SMS (short messaging service) alerts to keep existing and prospective investors updated on corporate milestones -- text 905-580-4170 to opt in;
• Targeted opt-in e-mail provides company news, clinical developments and financing updates -- e-mail: sfarooquoi@hemostemix.com;
• Investor platforms and exchanges are designed to increase Hemostemix's visibility, providing due diligence level information that retail and institutional audiences seek about the company's investment opportunities.

"Hemostemix has sold forward $1,143,983 in therapy convertible debenture year to date," said Thomas Smeenk, chief executive officer. "Frost and Sullivan awarded our company the Biotechnology Company of the Year Award, Asia, in 2007, for VesCell achievements. Now, with 498 treatments, 11 peer-reviewed publications, including seven clinical studies of 318 subjects, including phase II results that validate our patients' testimonials, we are ramping up sales in Florida, investor outreach and patient engagement simultaneously. VesCell won the World Economic Forum Technology Pioneer Award because it regenerates new circulation in the body where that need is signalled. Next week, I'm down to Florida to meet with cardiologists who have done their homework -- stay tuned," Mr. Smeenk said.

Campaign strategy and key highlights -- testimonials and publications storytelling:

• Real patient testimonials about improved cardiac function, reduction of pain and ulcer healing make the science and treatment relatable and compelling:
  • TIME Magazine highlighted VesCell recipient Bob Grinstead in Take Heart;
  • Watch six-time Grammy award winner and VesCell recipient Howie Lindeman;
  • Watch Beefsto's Founder, VesCell patient No. 57, Neim Malo;
• Platform utilization:
  • Instagram and Facebook: Hemostemix has shared emotionally driven visuals and success narratives to connect directly with patients, caregivers and broader communities;
  • LinkedIn: Tailored for professionals and investors, Hemostemix is highlighting its clinical milestones, innovations and corporate positioning;
  • X: Mr. Smeenk, at HeartRepairGuy, is providing quick, timely updates, and engagement with practitioners and investor audiences;
  • YouTube: Hemostemix posts its longer-form video content, including its weekly webinars and VesCell patient testimonials;
• Results emphasized in posts:
  • Cardiac improvements of up to a 47.1-per-cent increase in ejection fraction (LVEF per cent) in dilated cardiomyopathy patients after one treatment, Schubart et al., Stem Cell Research and Therapy;
  • Phase II CLTI: a 99-per-cent reduction in ulcerating wounds size, reduced from a mean of 146 square millimetre (mm) to 0.48 square mm by the end of month 3 (p equal to 0.01), Henderson et al., JBRES1876.
• Dual-audience targeting -- campaign bridges two primary goals:
  • Patient Recruitment: Demonstrating hope, safety, and effectiveness of VesCell(TM) for no-option CLTI, PAD, and heart patients.
  • Liquidity for Investors: Educating investors and shareholders about the HEM's asymmetrical investment upside, using scientifically validated results and milestones achieved.

About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell (ACP-01). A recent peer-reviewed article in Cells (June 29, 2025) provides the scientific foundation for how ACP-01 and NCP-01 may enhance brain-computer interface performance by reducing inflammation, fostering angiogenesis and synaptic plasticity, and potentially extending implant longevity. Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer-reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure and angina. Hemostemix completed its phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared with a five-year mortality rate of 50 per cent in the CLTI patient population, the University of British Columbia and University of Toronto reported to the 41st meeting of vascular surgeons: 0 per cent mortality, cessation of pain, wound healing in 83 per cent of patients followed for up to 4.5 years, as a midpoint result.

We seek Safe Harbor.